Interim Report on Business Performance (Fair Disclosure)
※ The following are interim figures, and may be different from final data.
1. Details of business performance in KRW mn, %
Category Current period Previous period Changes over previous period (%) Same period of last year Changes over same period of last year (%)
(4Q.21) (3Q.21) (4Q.20)
Sales Current 142,387 142,256 0.1% 138,552 2.8%
Cumulative 559,145 416,758 - 560,964 -0.3%
Operating income Current -17,823 -13,951 -27.8% -5,864 -203.9%
Cumulative -54,327 -36,504 - 5,598 Turned into a deficit
Net income from continuing operation before income tax Current -126,114 -7,811 -1514.6% -14,650 -760.8%
Cumulative -139,339 -13,225 - -10,022 -1290.3%
Net income Current -93,172 -4,461 -1988.6% -19,073 -388.5%
Cumulative -98,892 -5,720 - -13,105 -654.6%
- - - - - -
2. Details of information released Information provider CP Team
Information recipients Institutional and individual investors, analysts and the media
Date & time of information released Feb. 17, 2022, 17:17(+Seoul time)
Title and place of event held -
3. Contact points (department/phone number) CP Team(02-526-3357)
4. Other matters to be factored into investment decisions
- The above results are separate financial statements based on K-IFRS.

- Above results prior to an external review are subject to change after a review by external auditors.

- Accumulated amount of the net profit from continuing operation before income tax in current term(4Q. 21) includes 75,439 million(KRW) of loss on valuation of derivative instruments financial liabilities related to convertible bonds.
※ Related disclosure -

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Il Dong Pharmaceutical Co. Ltd. published this content on 17 February 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 17 February 2022 08:53:04 UTC.